The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Share News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 150.00
Bid: 140.00
Ask: 160.00
Change: 0.00 (0.00%)
Spread: 20.00 (14.286%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 150.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Shepherd Neame losses cut; Beximco to sell Covid pill

Tue, 09th Nov 2021 22:01

(Alliance News) - The following is a round-up of updates by London-listed companies not separately reported by Alliance News:

----------

Shepherd Neame Ltd - Faversham, Kent-based brewer and pub chain - Cuts annual pretax loss to GBP16.4 million, narrowed from GBP21.0 million the year before. Revenue shrinks to GBP86.9 million, down 26% year-on-year from GBP118.2 million. Notes that beer volume has been resilient throughout the pandemic and new on-trade customers have been obtained since re-opening. Highlights encouraging start to the new financial year, with strong demand for food and accommodation since July. Drinks trade is also recovering since the return to offices in London from September.

"We are greatly encouraged by the customer response since re-opening and are confident that beer and pubs remain every bit as core to British life as pre-pandemic," says Chief Executive Jonathan Neame. "We face challenges ahead, particularly with supply chain and inflationary pressures. That said, we are confident that the long term fundamental drivers for the business remain strong, including the ongoing infrastructure investment in our heartland, anticipated local population growth, changes in consumer and workplace trends, and our position at the centre of the community."

----------

Nostrum Oil & Gas PLC - oil & gas company - Extends forbearance agreement to Nov 26 from Nov 9 previously. The exploration and production company, which operates in the Caspian Basin area in eastern Europe, entered forbearance talks back in August 2020 after failing to pay interest due on its 8.0% senior notes due 2022 and 7.0% senior notes due 2025. It then struck a deal in October 2020. At the time, Nostrum said the forbearances included agreeing not to accelerate the notes' obligations as a result of the missed interest payments. Since then the expiry of the forbearance has been extended several times.

----------

Amte Power PLC - developer and manufacturer of lithium-ion and sodium-ion battery cells - Awarded small grant by Scottish government as part of its aim to achieve zero emissions from heavy duty vehicles such as buses, lorries and construction vehicles. The project will involve AMTE designing a specific battery module for the Ultra Energy cell. Chief Executive Kevin Brundish comments: "The electric vehicle market has not surprisingly been a significant focus throughout COP26. The Scottish government have been at the forefront of this debate and we are delighted to be participating in the zero emission heavy duty vehicles project."

----------

System1 Group PLC - marketing and brand consultancy based in London - Files a complaint for trademark infringement against System1 LLC over the infringing use of its name. "The company takes the protection of its unique intellectual property very seriously and believes such ongoing and expanding use by the opposing party is likely to cause significant confusion with System1 Group PLC and its registered marks and, moreover, constitutes intentional infringement, in violation of relevant US federal and state trademark laws as well as trademark laws in the UK, the EU and other countries," the company explains. The consultancy firms adds it believes it has a "compelling" case against the opposing party.

----------

Travel Chapter Holdings PLC - Bideford, Devon-based online holiday rental platform - Postpones proposed initial public offering due to "market volatility". The travel firm was initial planning to float on the London Stock Exchange's AIM market in mid-November. "Although Travel Chapter received considerable institutional investor support for the group's business model, growth strategy and management team, the board and shareholders have decided that proceeding with an initial public offering in this period of market volatility is not in the best interests of the group and its stakeholders," the company announces. Travel Chapter owns the brand holidaycottages.co.uk.

----------

Crossword Cybersecurity PLC - Richmond, England-based cyber security and risk-focused technology commercialisation company - Partners with Darkbeam to help improve Crossword's third-party risk management platform, Rizikon. Crossword will integrate Darkbeam's cyber risk ratings into the platform, helping organisations to further minimise the risk of digital threat. Rizikon users will be able to see the headline cyber risk rating on each supplier's scorecard. Crossword Sales Director Sean Arrowsmith says: "We are very pleased to partner with Darkbeam and help Rizikon customers further understand and manage the cyber risks that may exist in their supply chains. All too often these risks are unknown and only exposed when a cyber event occurs."

----------

Beximco Pharmaceuticals Ltd - Bangladesh-based pharmaceutical company - Is to begin selling the world's first generic version of Merck's coronavirus pill, molnupiravir. The drug is the first anti-viral pill for Covid-19 that can be taken at home and was recently developed by US firms Ridgeback Biotherapeutics LP and Merck & Co Inc. Beximco's branded generic version of molnupiravir will be marketed as Emorivir. The drug is for people who have had a positive Covid test and have at least one risk factor for developing severe illness, such as obesity, being over the age of 60, diabetes or heart disease. The UK's Medicines & Healthcare products Regulatory Agency said the drug is safe and effective at reducing the risk of hospital admission and death in people with mild to moderate Covid who are at extra risk from the virus. As an oral treatment that can be administered at home, molnupiravir has the "potential to have a significant impact on the treatment paradigm for Covid-19", Beximco states.

"The launch of a generic version of molnupiravir, the world's first oral antiviral drug to treat Covid-19, is another example of Beximco Pharma's ability to rapidly respond to make affordable treatments available to patients suffering from Covid-19. This is a great achievement for the company and one which we believe could play an important role in combating the pandemic, especially in low- and middle-income countries where access to vaccines has been limited," comments Managing Director Nazmul Hassan.

----------

Induction Healthcare Group PLC - healthcare technology company - Wins two-year contract to provide communications services to support the virtualisation of the UK benefits system. The contract, awarded by the Department of Work and Pensions, includes options for the department to extend the agreement term for up to a further two years. The contract value is for up to GBP2.6 million for the initial two years, totalling up to GBP5.2 million for the full four years. Chief Executive of Induction James Balmain comments: "This is our first major contract outside of the healthcare space and exemplifies the versatility of Induction's platforms as we look to expand from the secondary healthcare market".

----------

Netcall PLC - Bedford-based customer engagement software provider - Redeems GBP3.5 million of its existing GBP7.0 million loan note with BGF. The loan note was issued by the company to part fund the acquisition of MatsSoft in August 2017 and is repayable on or before March 2025. The interest cost resulting from the early redemption is GBP300,000 and the repayment will reduce the annual interest costs of the loan note from GBP600,000 to GBP300,000, Netcall explains.

----------

Castillo Copper Ltd - Perth, Australia-based exploration company - Says it is seeing "significant advances" in progressing its operations in Queensland and Zambia. Has samples collected and assessed for the extent of pegmatite outcropping at Picasso Lithium project, Western Australia. At its Luanshya project in Zambia, notes work now focused on formulating the inaugural drilling campaign. "We are pleased to report that we have made significant advances on several fronts in our copper operations in Queensland and Zambia. Specifically, the team on site at the Arya Prospect have overcome harsh conditions to progress our pioneering drilling campaign forward," comments Managing Director Simon Paull.

----------

Faron Pharmaceuticals Oy - Turku, Finland-based clinical stage biopharmaceutical company - Awarded EUR3.8 million in damages in arbitration case against Rentschler Biopharma. The Arbitration Institute of the Stockholm Chamber of Commerce ruled in favour of Faron. Faron was seeking damages from Rentschler for the termination of an agreement concerning the manufacturing of acute respiratory distress syndrome drug Traumakine. In October 2019, Rentschler had terminated the agreement to manufacture the active ingredient in Traumakine. After investigation, Faron concluded that the termination of the agreement breached the underlying agreement between the parties.

----------

BlueRock Diamonds PLC - Kareevlei diamond mine in the Kimberley region of South Africa - Reiterates confidence in achieving targeted production guidance of 22,000 to 26,000 carats, having produced 19,362 carats as at November 3. Says the Company is focused on completing an expansion project aimed at increasing tonnages at Kareevlei to provide the economies of scale to turn the mine into a "highly cash generative asset". Highlights "significant cost and operating efficiency benefits" anticipated once the new plant is running at capacity.

----------

Genedrive PLC - molecular diagnostics company - Narrows annual loss to GBP700,000 from GBP19.4 million the prior year. Revenue falls back below the million mark to GBP687,000 from GBP1.1 million. Notes short term outlook is centred on launch of two POC products: AIHL and CoV-POC. "We are at an exciting phase for the company with both the AIHL and CoV-POC products about to enter their commercial stages. Our balance sheet is strengthened following the recent equity raise and we are well placed to drive shareholder value going forwards," explains Chief Executive David Budd.

----------

AEW UK REIT PLC - UK commercial property investor - Buys 12 acre Central Six Retail Park in Coventry for GBP16.4 million. The purchase price reflects a net initial yield of around 11%, with an anticipated reversionary yield of circa 12.5%, AEW highlights. "At present the retail warehouse sector is providing some interesting opportunities, often underpinned by alternative use value, and occupied by tenants that have shown resilience during the pandemic. We are pleased to add this asset to the portfolio and will continue to target acquisitions where we believe valuations offer the opportunity to deliver both strong income and capital performance," says Portfolio Manager Alex Short.

----------

SVM UK Emerging Fund PLC - investor in small listed companies in the UK - Outperforms interim net asset value benchmark in a resilient first half. In the six months ended September 30, net asset value gained 17% to 145.7p per share, compared to a return of 8.4% at 125.00p on Mar 31 in the IA UK All Companies Sector Average Index. Growth was underpinned by positive contributions from Watches of Switzerland, Alpha FX Group, Dianomi, Reach and Dechra Pharmaceuticals. "The sharp recovery in the UK economy is creating value in some disruptive businesses," notes Chair Peter Dicks.

----------

Fidelity Special Values PLC - aims for capital growth by investing in special situations - Hikes full year dividend to 6.67 pence, an increase of 15% over the dividend of 5.80 pence paid in the prior year. The payout uplift follows net asset value growth of 56% for the year ended August 31, outperforming the benchmark index, which returned 27%. NAV per share hit 304.79p at year end, from 199.81p the previous year. "The year under review was an extraordinary one, in terms of the global and external factors affecting the companies in which we invest, the broader market, the daily lives of our shareholders, and their personal investments. This in turn led to extraordinary changes in investor confidence and sentiment leading to a remarkable, if uneven, recovery of asset prices," comments Chair Andy Irvine.

----------

Amryt Pharma PLC - biopharmaceutical company focused on developing novel treatments for rare diseases - Last Wednesday, reaffirms full year revenue guidance in range between USD220 million and USD225 million. The forecast revenue range would represent annual growth between 20% and 23%. Amryt posts third quarter revenue of USD56.5 million, up 15% year-on-year. Gross profit grows to USD29.3 million from USD22.3 million a year before. "Overall, the results demonstrate the strong growth we are experiencing across our business and represent our seventh consecutive quarter of positive earnings before interest, tax, depreciation and amortisation generation and this performance has been delivered despite the challenging Covid pandemic," says Chief Executive Joe Wiley.

----------

Standard Life Investments Property Income Trust Ltd - commercial property investor - Last Thursday, maintains third quarter dividend at 0.8925 pence per share. For the quarter, net asset value per share rises to 93.1p on September 30, from 88.3p on June 30. Says portfolio valuation increased by 4.7% on a like-for-like basis during the three months.

----------

Asia Wealth Group Holdings Ltd - Asia-focused investor in wealth management businesses - Last Friday, posts a slight rise in interim pretax profit to USD123,000 from USD117,000 a year before. The improvement was principally attributed to higher revenue, which climbed 5.1% to USD940,000. States that the group is "continuing to forge new revenue generating relationships, as well as expanding revenue creating opportunities", and is seeking new partnerships with firms in the same and new sectors.

----------

By Will Paige; willpaige@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
6 Nov 2023 11:03

IN BRIEF: Faron Pharmaceuticals starts Phase 2 of Bexmab trial

Faron Pharmaceuticals Ltd - Finland-based clinical-stage biopharmaceutical company - Initiates Phase 2 of Bexmab study investigating humanised antibody bexmarilimab in patients with aggressive myeloid leukemias. Says it has selected hypomethylating agents-refractory or relapsed myelodysplastic syndromes (MDS) as the initial indication, based on US Food & Drug Administration guidance. Phase 1 data "demonstrated that optimal target engagement can be achieved with three milligrams per kilogram dosing" with both three and six milligram cohorts showing the "highest immune activation", while the drug produced a 50% remission rate in doublet dose cohorts.

Read more
6 Nov 2023 10:31

Faron reveals details of next stage of bexmarilimab study

(Sharecast News) - Faron Pharmaceuticals announced on Monday that, following guidance from the US Food and Drug Administration (FDA), the initial indication for phase two advancement in the study investigating bexmarilimab in combination with standard of care, would focus on hypomethylating agents (HMAs)-refractory or relapsed myelodysplastic syndromes (MDS).

Read more
30 Oct 2023 15:56

TRADING UPDATES: Bezant optimistic after Hope & Gorob estimate

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
11 Oct 2023 14:53

Faron Pharmaceuticals upbeat on latest data in blood cancer trials

(Sharecast News) - Faron Pharmaceuticals announced encouraging updated data from its ongoing phase one and two 'BEXMAB' study into relapsed or refractory (r/r) acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) treatments on Wednesday.

Read more
11 Oct 2023 14:01

IN BRIEF: Faron Pharmaceuticals' Bexmarilimab shows 50% remission rate

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical-stage biopharmaceutical company - Says Bexmarilimab study shows 50% remission rate for patients with in relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes. Says eight of eleven patients were complete responders or complete responders with incomplete blood recovery. Adds Bexmarilimab continues to be well-tolerated at all tested dose levels, as no dose-limiting toxicity has been observed.

Read more
21 Sep 2023 14:45

Faron Pharmaceuticals names interim chief medical officer

(Sharecast News) - Cancer immunotherapy-focussed biopharmaceutical firm Faron Pharmaceuticals named Dr Birge Berns as its interim chief medical officer on Thursday, with the transition becoming effective on 22 September, with Dr Berns operating from the UK.

Read more
21 Sep 2023 12:12

TRADING UPDATES: Faron appoints Birge Berns as interim medical officer

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
15 Sep 2023 15:46

UK shareholder meetings calendar - next 7 days

Monday 18 September 
Baillie Gifford US Growth Trust PLCAGM
Inteliqo LtdAGM
LendInvest PLCAGM
Rosslyn Data Technologies PLCGM re fundraise
Tuesday 19 September 
Africa Opportunity Fund LtdAGM
Aston Martin Lagonda Global Holdings PLCGM re supply arrangement with Lucid Group Inc
Augmentum Fintech PLCAGM
Beacon Rise Holdings PLCAGM
Begbies Traynor Group PLCAGM
Chill Brands Group PLCAGM
DP Aircraft I LtdAGM
Great Southern Copper PLCAGM
Manolete Partners PLCAGM
Moonpig Group PLCAGM
Oxford Instruments PLCAGM
ProCook Group PLCAGM
SRT Marine Systems PLCAGM
Unicorn Mineral Resources PLCAGM
Wednesday 20 September 
Accsys Technologies PLCAGM
Frasers Group PLCAGM
Games Workshop Group PLCAGM
Hidong Estate PLCAGM
IG Group Holdings PLCAGM
Ilika PLCAGM
Nippon Active Value Fund PLCGM re assets rollover
Quiz PLCAGM
Seed Innovations LtdAGM
STS Global Income & Growth Trust PLCAGM
Thursday 21 September 
Ascent Resources PLCGM re audited annual accounts
Intercede Group PLCAGM
Kore Potash PLCGM re capital raise
Liontrust Asset Management PLCAGM
Mercia Asset Management PLCAGM
Molecular Energies PLCAGM
Oberon Investments Group PLCAGM
Pelatro PLCGM re AIM cancellation
Sosandar PLCAGM
Thruvision Group PLCAGM
Trakm8 Holdings PLCAGM
Van Elle Holdings PLCAGM
Friday 22 September 
Argos Resources LtdGM re members voluntary liquidation
B&M European Value Retail SAGM re appointing Lasry as director
Faron Pharmaceuticals LtdEGM re election of new board members
Stranger Holdings PLCAGM
SysGroup PLCAGM
TI Fluid Systems PLCGM re waiver resolution
Odyssean Investment Trust PLCAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
5 Sep 2023 14:22

Evgen Pharma hires interim CFO from Faron, chair to retire this month

(Alliance News) - Evgen Pharma on Tuesday said Non-Executive Chair Barry Clare will retire at its next board meeting, and announced the hiring of interim Chief Financial Officer Toni Hanninen.

Read more
29 Aug 2023 10:23

AIM WINNERS & LOSERS: Pelatro plummets on delisting plans

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
29 Aug 2023 10:15

Faron shares surge on FDA drug designation; loss widens on costs

(Alliance News) - Faron Pharmaceuticals Ltd on Tuesday said its interim loss widened on higher costs but saw shares soar after it gained a US Food & Drug Administration orphan drug designation for Bexmarilimab.

Read more
22 Aug 2023 15:46

UK earnings, trading statements calendar - next 7 days

Wednesday 23 August 
Angling Direct PLCTrading Statement
Costain Group PLCHalf Year Results
Thursday 24 August 
Benchmark Holdings PLCQ3 Results
CRH PLCHalf Year Results
Harbour Energy PLCHalf Year Results
Hays PLCFull Year Results
Hunting PLCHalf Year Results
James Cropper PLCHalf Year Results
Macfarlane Group PLCHalf Year Results
Princess Private Equity Holding LtdHalf Year Results
Redcentric PLCFull Year Results
South32 LtdFull Year Results
Tribal Group PLCHalf Year Results
Friday 25 August 
no events scheduled 
Monday 28 August 
no events scheduled 
Tuesday 29 August 
Amaroq Minerals LtdHalf Year Results
Bunzl PLCHalf Year Results
Dalata Hotel Group PLCHalf Year Results
Faron Pharmaceuticals LtdHalf Year Results
PureTech Health PLCHalf Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
19 Jul 2023 10:27

Faron Pharmaceuticals sees positive data from phase 1 BEXMAB trial

(Alliance News) - Faron Pharmaceuticals Ltd on Wednesday said data from its phase 1 BEXMAB study has shown positive data.

Read more
29 Jun 2023 18:55

TRADING UPDATES: Ecofin US Renewables expects to pay reduced dividend

(Alliance News) - The following is a round-up of updates by London-listed companies, issued Thursday and not separately reported by Alliance News:

Read more
9 Jun 2023 14:34

TRADING UPDATES: Medica shareholders back takeover; Arecor optimistic

(Alliance News) - The following is a round-up of updates by London-listed companies, issued Friday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.